SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SCLN
0.00 (0.00%)
Oct 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 6.47 - 11.71
Open     -
Vol / Avg. 0.00/402,766.00
Mkt cap 344.72M
P/E 22.19
Div/yield     -
EPS 0.31
Shares 50.25M
Beta 1.87
Inst. own 81%
Nov 9, 2015
Q3 2015 SciClone Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 9, 2015
SciClone Pharmaceuticals Inc at Aegis Capital Growth Conference - 2:25PM EDT - Add to calendar
Sep 10, 2015
SciClone Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 10, 2015
SciClone Pharmaceuticals Inc at BioCentury NewsMakers in the Biotech Industry Conference
Aug 10, 2015
Q2 2015 SciClone Pharmaceuticals Inc Earnings Call - Webcast
Aug 10, 2015
Q2 2015 SciClone Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -10.60% 18.70%
Operating margin -12.80% 19.28%
EBITD margin - 19.95%
Return on average assets -8.53% 13.94%
Return on average equity -9.96% 16.70%
Employees 570 -
CDP Score - -


950 Tower Ln Ste 900
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, including China and the rest of the world (the United States and Hong Kong). The Company's lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin, therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc, a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex, a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications, and RapidFilm, an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Officers and directors

Jon S. Saxe Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Wilson W. Cheung Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 46
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 51
Bio & Compensation  - Reuters
Robert S. King Ph.D. Senior Vice President - Product Development and Supply Chain
Age: 48
Bio & Compensation  - Reuters
Raymond A Low CPA Vice President - Finance, Controller
Age: 58
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Age: 52
Bio & Compensation  - Reuters
Lan Xie CPA Vice President - Finance, China Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters